Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients: A propensity score matched analysis

BACKGROUND: Remdesivir is the only antiviral agent approved for the treatment of hospitalized coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen. Studies show conflicting results regarding its effect on mortality. METHODS: In this single center observational study, we include...

Descripción completa

Detalles Bibliográficos
Autores principales: Karolyi, Mario, Kaltenegger, Lukas, Pawelka, Erich, Kuran, Avelino, Platzer, Moritz, Totschnig, David, Koenig, Franz, Hoepler, Wolfgang, Laferl, Hermann, Omid, Sara, Seitz, Tamara, Traugott, Marianna, Arthofer, Sigrun, Erlbeck, Lea, Jaeger, Stefan, Kettenbach, Alina, Assinger, Alice, Wenisch, Christoph, Zoufaly, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610353/
https://www.ncbi.nlm.nih.gov/pubmed/36301355
http://dx.doi.org/10.1007/s00508-022-02098-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610353/
https://www.ncbi.nlm.nih.gov/pubmed/36301355
http://dx.doi.org/10.1007/s00508-022-02098-9

Ejemplares similares